Condition
Hand and Foot Syndrome
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (2)
P 3 (1)
Trial Status
Unknown2
Completed1
Not Yet Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07457671Phase 2Not Yet RecruitingPrimary
TAR-0520 Gel in Hand and Foot Syndrome
NCT06188000Not ApplicableUnknown
Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine
NCT05641246Phase 2CompletedPrimary
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine
NCT00767689Not ApplicableTerminatedPrimary
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
NCT05327751Phase 3UnknownPrimary
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
Showing all 5 trials